Description: TNF-RI, Human, mAb MR1-2

Specifications:

Catalog number	HM2005
Product type	Monoclonal antibodies
Quantity	100 µg
Formulation	1 ml (100 μg/ml) 0.2 μm filtered protein G purified antibody solution in PBS containing 0.1% bovine serum albumin. The endotoxin concentration is < 24 EU/mg, determined with HIT302 LAL Assay.
Application	Flow cytometry, Functional studies
Use	Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
Immunogen	Extracellular part of TNF-R55
Isotype	Mouse IgG1
Species	Human
Cross reactivity	Cynomolgus monkey - Yes, Rhesus monkey - Yes
Alias	Tumor necrosis factor receptor superfamily member 1A, Tumor necrosis factor receptor type I Gene name: TNFRSF1A
Positive Control	Human lymphnodes or PHA activated T cells
References	1. Leeuwenberg, JFM et al; Slow release of soluble TNF-Receptors by monocytes in vitro. J Immunol 1994, 152: 4036 2. Leeuwenberg, JFM et al; Lipopolysaccharide LPS-mediated soluble TNF-Receptor release and TNF-Receptor expression by monocytes; role of CD14, LPS binding protein and bactericidal/permeability-increasing protein. J Immnol 1994, 152: 5070 3. Marchetti, L et al; Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J Biol Chem 2004, 279: 32869
Storage and stability	Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
Precautions	For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hbt is not responsible for any patent infringements that might result with the use of or derivation of this product.
Disease	Autoimmunity, Gastroenterology

Hycult Biotech当您在研究项目中寻找中小企业合作伙伴时，Hycult Biotech是您的首选合作伙伴。凭借我们的背景和专业知识，我们可以为您的项目增值：从成为财团的负责人到成为科学项目的推动力，我们都有在科学项目中扮演不同角色的经验。由于我们遍布全球的广泛网络，我们可以在寻找研究项目的合作伙伴方面发挥核心作用。我们可以协助撰写建议书或建立财团。获得科学资助的我们的研究活动示例：生物标志物测定法的发展抗体的表征。从概念到最终产品。Hycult Biotech代表什么从1994年开始创建分析，抗体和蛋白质。根据ISO13485指南开发和生产（IVD）套件。关于复杂基质中蛋白质难以测量的广泛知识。制药和生物技术行业的伴侣诊断合作伙伴。 Hycult Biotech目前参与以下研究项目OPZuid：Zuid-Nederland行动纲领Hycult Biotech利用“ OP Zuid”资金，目前正在研究开发针对类风湿性关节炎和骨关节炎的创新诊断测试的可能性。使用该测试可以更好地监视患者及其疾病活动，严重程度和治疗反应。更好的诊断结合个性化治疗将大大改善这些患者的生活质量。相关：缓解慢性自身免疫性疾病的预防RELENT项目提供了探索新的研究领域并加深其对自身免疫和炎症领域的见解的机会。Hycult Biotech在该主题非常适合的慢性炎性疾病领域中不断扩展产品。寻找与RA，IBD和AASV相关的新型靶蛋白将为进一步进入诊断领域提供机会。 Hycult Biotech已成功参与以下研究项目-DIREKT：解除血管内固有免疫反应，改善慢性肾脏病的治疗方式-PREDICCt：糖尿病和与糖尿病相关的心血管并发症的预测和早期诊断的生物标志物-TranSVIR：转化为血管炎症和修复的科学-指示：慢性自身免疫的传染性诱因 有关科学赠款和合作的更多信息，请参见以下传单：